COMMUNIQUÉS West-GlobeNewswire

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
26/02/2026
JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
26/02/2026
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that [...]
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
26/02/2026
Physician Interview Now Available Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint [...]
OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers
26/02/2026
MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a [...]
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
26/02/2026
Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first [...]
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
26/02/2026
Results from IV Phase 1 SAD/MAD Trial Expected in 2026 JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent [...]
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
26/02/2026
-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading [...]
Highridge Medical Begins a Limited Launch of the activL® Lumbar Disc with Strong Early Surgeon Adoption
26/02/2026
Surgeons complete initial cases at premier disc replacement centers across the United States. WESTMINSTER, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Highridge Medical, a leading privately held global spine company with a [...]
GATC Health Strengthens Commercial and Pharma Strategy Leadership to Accelerate Market Adoption of Its AI Platform
26/02/2026
Mark Flather and Dr. Fred Brown join to expand adoption of Derisq™ and Operon™, delivering AI-powered risk prediction and portfolio optimization for biotech investors and pharmaceutical partners. Appointments come as [...]
The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month
26/02/2026
STUDIO CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Every March, the International Myeloma Foundation (IMF) leads Myeloma Action Month — an annual global awareness campaign that raises awareness and inspires action [...]
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026 Initial data from [...]
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
26/02/2026
Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced [...]
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
26/02/2026
Recognized expert in cancer biology, RNA biology and translational therapeutics with 20 years of experience in preclinical oncology drug discovery and development TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE [...]
Glow Holdings, Inc. Launches New Corporate Website
26/02/2026
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Glow Holdings, Inc. (OTC: GLOH), doing business as GlohCo, an emerging healthtech company developing AI-powered software and data-driven tools for mental health, behavioral [...]
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
26/02/2026
Accepted Abstract Highlights Metabolic Response Observations Following Chemotherapeutic Drug-Delivery via the TAMP™ Therapy Platform in Patients Diagnosed with Locally Advanced Pancreatic Cancer MOUNTAIN VIEW, Calif., [...]
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
26/02/2026
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior [...]
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
26/02/2026
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
FibroBiologics to Present at the BIO Investment & Growth Summit
26/02/2026
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
26/02/2026
Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions ASHBURN, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd. ( [...]

Pages